NO20081125L - Antitumor middel - Google Patents

Antitumor middel

Info

Publication number
NO20081125L
NO20081125L NO20081125A NO20081125A NO20081125L NO 20081125 L NO20081125 L NO 20081125L NO 20081125 A NO20081125 A NO 20081125A NO 20081125 A NO20081125 A NO 20081125A NO 20081125 L NO20081125 L NO 20081125L
Authority
NO
Norway
Prior art keywords
antitumor agent
compound
cholestanol
sugar
exhibits
Prior art date
Application number
NO20081125A
Other languages
English (en)
Inventor
Shin Yazawa
Touyou Nishimura
Takashi Nakagawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of NO20081125L publication Critical patent/NO20081125L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er tilveiebragt en sukker-kolestanol-forbindelse som lett kan syntetiseres og som oppviser en tilfredsstillende antitumor-aktivitet. Et anticancer-middel inneholdende, som en aktiv bestanddel, en kolestanol- forbindelse representert ved den følgende formel (1): eller et cyklodekstrin-inklusjonskompleks inneholdende forbindelsen.
NO20081125A 2005-09-02 2008-03-04 Antitumor middel NO20081125L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005255517 2005-09-02
PCT/JP2006/317316 WO2007026869A1 (ja) 2005-09-02 2006-09-01 抗癌剤

Publications (1)

Publication Number Publication Date
NO20081125L true NO20081125L (no) 2008-05-16

Family

ID=37808952

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081125A NO20081125L (no) 2005-09-02 2008-03-04 Antitumor middel

Country Status (24)

Country Link
US (1) US7968116B2 (no)
EP (1) EP1921086B1 (no)
JP (1) JP5011113B2 (no)
KR (1) KR101292539B1 (no)
CN (1) CN101253192B (no)
AR (1) AR057793A1 (no)
AU (1) AU2006285678B2 (no)
BR (1) BRPI0615196A2 (no)
CA (1) CA2621377C (no)
CY (1) CY1115196T1 (no)
DK (1) DK1921086T3 (no)
ES (1) ES2459767T3 (no)
HK (1) HK1115140A1 (no)
HR (1) HRP20140439T1 (no)
IL (1) IL189752A (no)
MY (1) MY155903A (no)
NO (1) NO20081125L (no)
PL (1) PL1921086T3 (no)
PT (1) PT1921086E (no)
RU (1) RU2410389C2 (no)
SI (1) SI1921086T1 (no)
TW (1) TWI373473B (no)
WO (1) WO2007026869A1 (no)
ZA (1) ZA200802813B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ300722B6 (cs) * 2006-09-27 2009-07-22 Univerzita Karlova v Praze, Prírodovedecká fakulta Zpusob prípravy inkluzního komplexu pentacyklických a tetracyklických terpenoidu a farmaceutického prostredku obsahujícího tento inkluzní komplex, inkluzní komplex pentacyklického nebo tetracyklického terpenoidu a farmaceutický prostredek obsahující
TWI492759B (zh) * 2008-03-05 2015-07-21 Otsuka Pharma Co Ltd 膽甾烷醇衍生物之併用用途
NZ594996A (en) 2009-03-04 2014-02-28 Otsuka Pharma Co Ltd Cholestanol derivative for combined use
US9968583B2 (en) 2009-03-30 2018-05-15 Eisai R & D Management Co., Ltd. Method of manufacture of liposome composition
WO2010113984A1 (ja) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物
CA2865983C (en) 2012-03-02 2021-10-19 The Board Of Trustees Of The University Of Illinois Potent anticancer activity via dual compound activation
EP2822546B1 (en) 2012-03-06 2017-07-12 The Board of Trustees of the University of Illionis Procaspase combination therapy for treating cancer
CA2866021C (en) 2012-03-06 2020-09-22 The Board Of Trustees Of The University Of Illinois Procaspace 3 activation by pac-1 combination therapy
CN103349948B (zh) * 2013-06-21 2015-05-27 江南大学 一种植物甾烷醇微胶囊化方法
RU2544455C1 (ru) * 2013-12-30 2015-03-20 Федеральное государственное бюджетное учреждение "Государственный научный центр колопроктологии" Министерства здравоохранения Российской Федерации Способ закрытой геморроидэктомии с гофрирующим швом
CN105753923B (zh) * 2014-12-17 2017-09-29 富力 20(R)‑人参皂苷Rg3多酰基化衍生物、制备及其应用
WO2019099873A1 (en) 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS572300A (en) * 1980-06-09 1982-01-07 Tetsuo Suami Novel nitrosourea derivative
SE8902235D0 (sv) * 1989-06-20 1989-06-20 Haessle Ab Novel cyclodextrin inclusion complexes
JP4105258B2 (ja) * 1997-08-19 2008-06-25 大塚製薬株式会社 コレスタノール化合物及びこれを含有する医薬
JPH11160592A (ja) 1997-11-28 1999-06-18 Hitachi Cable Ltd 光ファイバケーブル用スペーサ
JP4351314B2 (ja) * 1998-12-24 2009-10-28 大塚製薬株式会社 コレスタノール化合物及びこれを含有する医薬
EP1647277A4 (en) * 2003-07-17 2011-09-21 Otsuka Pharma Co Ltd LIPOSOME CONTAINING GLYCOSIDE
PL1709063T3 (pl) * 2003-12-18 2008-06-30 Unibioscreen Sa Glikozylowane pochodne steroidowe o aktywności antymigracyjnej
JP2005225822A (ja) * 2004-02-13 2005-08-25 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤
KR100603814B1 (ko) * 2004-03-11 2006-07-25 바이오스펙트럼 주식회사 나노리포좀 조성물

Also Published As

Publication number Publication date
AU2006285678B2 (en) 2012-01-19
WO2007026869A1 (ja) 2007-03-08
CN101253192B (zh) 2011-05-04
RU2410389C2 (ru) 2011-01-27
DK1921086T3 (da) 2014-05-05
CN101253192A (zh) 2008-08-27
CA2621377A1 (en) 2007-03-08
ES2459767T3 (es) 2014-05-12
US20100292176A1 (en) 2010-11-18
CY1115196T1 (el) 2017-01-04
JPWO2007026869A1 (ja) 2009-03-12
AU2006285678A1 (en) 2007-03-08
HK1115140A1 (en) 2008-11-21
HRP20140439T1 (hr) 2014-06-20
PT1921086E (pt) 2014-04-29
ZA200802813B (en) 2009-10-28
IL189752A (en) 2013-07-31
US7968116B2 (en) 2011-06-28
AR057793A1 (es) 2007-12-19
KR20080043838A (ko) 2008-05-19
SI1921086T1 (sl) 2014-05-30
CA2621377C (en) 2013-10-22
EP1921086B1 (en) 2014-04-16
MY155903A (en) 2015-12-15
BRPI0615196A2 (pt) 2011-05-10
TW200738744A (en) 2007-10-16
KR101292539B1 (ko) 2013-08-20
TWI373473B (en) 2012-10-01
JP5011113B2 (ja) 2012-08-29
RU2008112676A (ru) 2009-10-10
EP1921086A4 (en) 2012-07-25
EP1921086A1 (en) 2008-05-14
PL1921086T3 (pl) 2014-09-30

Similar Documents

Publication Publication Date Title
NO20081125L (no) Antitumor middel
NO20081196L (no) Terapeutisk middel for diabetes
UA94065C2 (en) Dihydropseudoerythromycin derivatives
WO2009001060A3 (en) Use of compounds for preparing anti-tuberculosis agents
NO20070323L (no) Organiske forbindelser
HRP20120323T1 (en) Diarylhydantoin compounds
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
MX2009004766A (es) Derivados de espiroindolinona.
GB0521508D0 (en) Organic compounds
ATE433447T1 (de) Pyrimiidinverbindungen
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2008034736A3 (en) Oxindole derivatives as anticancer agents
MX2009012345A (es) Derivados de 3,3-espiroindolinona.
NO20081160L (no) Benzimidazoltiofen forbindelser
WO2007025098A3 (en) Triazole compounds and methods of making and using the same
NO20054787D0 (no) Indenderivater som farmasotiske midler
MX2007013623A (es) Preparacion externa para la piel.
TW200719922A (en) Skin lotion and wrinkle improving agent
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
WO2008009831A3 (fr) Derives de cyclodextrines amphiphiles
UA88956C2 (ru) Синергическая фунгицидная комбинация действующих веществ
WO2009064374A8 (en) Oral formulations of bis(thiohydrazide amides)
TW200621160A (en) Anti-termite agent
WO2009051223A1 (ja) 白内障処置のための医薬組成物
WO2007025089A3 (en) Triazole compounds and methods of making and using the same

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application